Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 7/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 11/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 9/20 | 0.37 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25335434 | 0.91 | CRBN (0.37) | NPY2RCRBNDDB1GSPT1KDM1A | |
| SCHEMBL30135903 | 0.88 | ALDH1A1 (0.40) | NPY2RCRBNDDB1KDM1A | |
| SCHEMBL25822081 | 0.86 | DDB1 (0.45) | NPY2RCRBNDDB1KDM1A | |
| SCHEMBL25035469 | 0.86 | CRBN (0.39) | NPY2RCRBNDDB1GSPT1OPRK1 | |
| SCHEMBL25334457 | 0.85 | DRD2 (0.43) | — | |
| SCHEMBL25336448 | 0.85 | DRD2 (0.43) | — | |
| SCHEMBL25301480 | 0.85 | CRBN (0.37) | CRBNDDB1GSPT1 | |
| SCHEMBL25262031 | 0.85 | CRBN (0.37) | CRBNDDB1GSPT1 | |
| SCHEMBL30135729 | 0.83 | CRBN (0.44) | CRBNDDB1GSPT1 | |
| SCHEMBL29013201 | 0.81 | CRBN (0.37) | NPY2RCRBNDDB1GSPT1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | NPY2R 4852/4885CRBN 2136/4885DDB1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.